Table 3.
Summary of antimicrobial resistance results in Campylobacter spp. isolated from poultry published in the last 5 years, within the five continents.
| Study | Region | Reference | Publishing year | No. of isolates | Resistance profile (%) |
|---|---|---|---|---|---|
| 1 | Africa | Karikari et al. | 2017 | C. jejuni 39 | AMP (100), C (84,6), CIP (69,2), CLX (100), CTX (87,2), ERY (100), GM (23,1), KA (28,2), NAL (38,5), NOR (48,7), SXT (92,3), T (100) |
| C. coli14 | AMP (100), C (64,3), CIP (64,3), CLX (85,7), CTX (85,7), ERY (100), GM (0), KA (28,6), NAL (7,4), NOR (0), SXT (92,9), T (92,9) | ||||
| C. iari 9 | AMP (100), C (55,6), CIP (100), CLX (100), CTX (100), ERY (100), GM (33,3), KA (33,3), NAL (100), NOR (77,8), SXT (88,9), T (100) | ||||
| 2 | North America | Kassem et al. | 2017 | C. jejuni 45 | CIP (15,6), ERY (20), S (11,1), T (64,4), TYL (33,3) |
| C. coli 155 | CIP (7,1), ERY (26,5), S (10,3), T (66,5), TYL (28,4) | ||||
| 3 | South America | Donado-Godoy et al. | 2014 | 29 | CIP (97), ERY (21), T (83) |
| 4 | South America | Panzenhagen et al. | 2016 | C. jejuni 44 | CIP (100), ENR (100) |
| C. coli 38 | CIP (100), ENR (100) | ||||
| 5 | South America | Vinueza-Burgos et al. | 2017 | C. jejuni 48 | CIP (97,9), ERY (4,2), GM (2,1), NAL (100), S (8,4), T (83,4) |
| C. coli 170 | CIP (100), ERY (25,8), GM (1,2), NAL (99,3), S (11,2), T (67,6) | ||||
| 6 | Asia | Han et al. | 2016 | C. jejuni160 | CIP (88,1), CLD (68,1), ERY (14,3), FFN (16,3), GM (47,5), LEV (78,1), S (43,8), T (79,4) |
| C. coli 130 | CIP (100), CLD (98,5), ERY (93,5), FFN (8,5), GM (90,8), LEV (98,5), S (17,8), T (98,5) | ||||
| 7 | Asia | Kottawatta et al. | 2017 | C. jejuni 20 | AMP (45), C (0), CIP (80), CLA (0), ERY (5), GM (10), NAL (80), NEO (10), S (5), SUL (0), T (85), TUL (5) |
| C. coli 45 | AMP (8,8), C (2,2), CIP (84,4), CLA (6,6), ERY (11,1), GM (2,2), NAL (84,4), NEO (8,8), S (4,4), SUL (2,2), T (24,4), TUL (6,6) | ||||
| 8 | Europe | Wieczorek e Osek | 2015 | C. jejuni 576 | CIP (74,8), ERY (0,9), T (46,5) |
| C. coli 575 | CIP (88,3), ERY (4), T (65,7) | ||||
| 9 | Europe | García-Sánchez et al. | 2018 | C. jejuni 55 | AZI (96), CIP (100), ERY (100), GM (100), NAL (100), T (98) |
| C. coli 19 | AZI (63), CIP (79), ERY (63), GM (95), NAL (100), T (100) | ||||
| C. lari 2 | AZI (0), CIP (100), ERY (0), GM (50), NAL (100), T (100) |
AMP ampicillin, AZI azithromycin, C chloramphenicol, CIP ciprofloxacin, CLA clarithromycin, CLD clindamycin, CLX cefalexin, CTX cefotaxime, ENR enrofloxacin, ERY erythromycin, FFN florfenicol, GM gentamicin, KA kanamycin, LEV levofloxacin, NAL nalidixic acid, NEO neomycin, NOR norfloxacin, S streptomycin, SUL sulfamethoxazole, SXT sulfamethoxazole/trimethoprim, T tetracycline, TUL tulathromycin